Full Breakdown
AbbVie Nears $11 Billion Acquisition of Apogee Therapeutics
6/20/2026, 8:31:24 PM
Deal Overview
On June 19 2024, AbbVie (ticker ABBV.N) entered advanced negotiations to acquire Apogee Therapeutics (ticker APGE.O) in an all-cash transaction valued at approximately $10.9 billion. The proposed price represents a roughly 60 % premium to Apogee’s closing share price on the preceding Thursday. According to the Financial Times, which cited people familiar with the matter, an official announcement could be issued as early as the following Monday, contingent on the completion of negotiations without last-minute issues.
Strategic Context for AbbVie
AbbVie’s interest in Apogee follows the recent FDA approval of pivekimab (sunirine-pvzy), a therapy for a rare blood cancer. The approval expands AbbVie’s oncology portfolio and underscores its broader strategy of strengthening pipelines in specialty therapeutics. Acquiring a company focused on inflammatory and immune diseases aligns with AbbVie’s objective to deepen its presence in those therapeutic areas.
Apogee Therapeutics Profile
Founded in 2022, Apogee Therapeutics develops treatments for inflammatory and immune disorders. The company’s lead candidate targets eczema and has entered late-stage development. In the month preceding the acquisition talks, Apogee secured a financing package of up to $1.3 billion from Blackstone Life Sciences to support the development and potential commercialization of this candidate. As of the latest LSEG data, Apogee’s market capitalization stood at about $6.81 billion, and its shares had risen 19.7 % year-to-date.
Deal Valuation and Financial Metrics
The cash consideration of $10.9 billion exceeds Apogee’s market value by roughly 60 % and would be funded entirely by AbbVie. The premium reflects both the strategic value AbbVie places on Apogee’s pipeline and the recent financing that de-risked the eczema program. The transaction would effectively double the market value of Apogee at the time of the offer. The premium calculation uses the Thursday closing price reported by LSEG.
Implications for the Inflammatory-Disease Market
Integrating Apogee’s eczema program into AbbVie’s portfolio could accelerate the availability of new treatments for skin inflammation, a segment where AbbVie currently has limited products. The acquisition may also enhance AbbVie’s competitive position against other large biopharma firms pursuing inflammatory-disease assets. For Apogee, the deal provides immediate access to AbbVie’s global development, manufacturing, and commercial infrastructure, potentially expediting the launch of its lead candidate.
Official Statements and Information Gaps
Neither AbbVie nor Apogee Therapeutics has released an official comment on the prospective transaction. The details reported stem from the Financial Times and unnamed sources familiar with the negotiations. Consequently, the exact terms, closing timeline, and regulatory requirements remain unconfirmed.
Next Steps
If negotiations conclude without further obstacles, AbbVie is expected to announce the transaction early next week. Subsequent steps will include shareholder approval, antitrust review, and the integration of Apogee’s assets into AbbVie’s existing operations.
